The EPS projection of Flex Pharma, Inc. (NASDAQ:FLKS) for quarter ended 2016-09-30 is $-0.74. Last week, the EPS forecast was $-0.74 against target of $-0.74, a month earlier. Two months ago, this estimate was $-0.74 versus forecast of $-0.74 three months earlier, implying a deviation of 0%.
Flex Pharma, Inc. (NASDAQ:FLKS) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 1, and 1, correspondingly.
EPS estimate downgrade for Flex Pharma, Inc. (NASDAQ:FLKS) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
Flex Pharma, Inc. (NASDAQ:FLKS) EPS target for the quarter closed 1 was $-0.74, based on 3 recommendations. As reported on 2016-05-04 the EPS was $-0.61. The change was $-0.02, implying a percentage deviation of -3.39%. The projections showed a standard deviation of 0.25.
Quarterly Sales Estimates
Flex Pharma, Inc. (NASDAQ:FLKS) yearly sales prediction for the fiscal 2016 stands at $0.263 and the median estimate is at $0.21. Almost 3 analysts issued sales target.
Highest sales target is $0.5 while the lowest target is $0.079 showing standard deviation of 0.215%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of -25.915%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. Flex Pharma, Inc. (NASDAQ:FLKS) announced that the deviation in forecast was -65.844%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...